These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23311607)

  • 1. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.
    Gao J; Zhao Y; Lv Y; Chen Y; Wei B; Tian J; Yang Z; Kong F; Pang J; Liu J; Shi H
    Cancer Cell Int; 2013 Jan; 13(1):2. PubMed ID: 23311607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2.
    Hu J; Nakhla H; Friedman E
    Int J Cancer; 2011 Jul; 129(2):307-18. PubMed ID: 20857490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirk kinase inhibition targets ovarian cancer ascites.
    Deng X; Hu J; Cunningham MJ; Friedman E
    Genes Cancer; 2014 May; 5(5-6):201-11. PubMed ID: 25061503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirk/dyrk1B Kinase in Ovarian Cancer.
    Friedman E
    Int J Mol Sci; 2013 Mar; 14(3):5560-75. PubMed ID: 23528858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice.
    Masuda T; Itoh K; Higashitsuji H; Higashitsuji H; Nakazawa N; Sakurai T; Liu Y; Tokuchi H; Fujita T; Zhao Y; Nishiyama H; Tanaka T; Fukumoto M; Ikawa M; Okabe M; Fujita J
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10885-90. PubMed ID: 22711815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirk regulates the exit of colon cancer cells from quiescence.
    Jin K; Ewton DZ; Park S; Hu J; Friedman E
    J Biol Chem; 2009 Aug; 284(34):22916-25. PubMed ID: 19542220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirk/Dyrk1B mediates survival during the differentiation of C2C12 myoblasts.
    Mercer SE; Ewton DZ; Deng X; Lim S; Mazur TR; Friedman E
    J Biol Chem; 2005 Jul; 280(27):25788-801. PubMed ID: 15851482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.
    Kokkorakis N; Zouridakis M; Gaitanou M
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
    Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
    [No Abstract]   [Full Text] [Related]  

  • 14. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288.
    Zou Y; Ewton DZ; Deng X; Mercer SE; Friedman E
    J Biol Chem; 2004 Jun; 279(26):27790-8. PubMed ID: 15075324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.
    Deng X; Ewton DZ; Friedman E
    Cancer Res; 2009 Apr; 69(8):3317-24. PubMed ID: 19351855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.
    Deng X; Mercer SE; Shah S; Ewton DZ; Friedman E
    J Biol Chem; 2004 May; 279(21):22498-504. PubMed ID: 15010468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling.
    Jin K; Lim S; Mercer SE; Friedman E
    J Biol Chem; 2005 Dec; 280(51):42097-105. PubMed ID: 16257974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
    Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
    Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcriptional activator Mirk/Dyrk1B is sequestered by p38alpha/beta MAP kinase.
    Lim S; Zou Y; Friedman E
    J Biol Chem; 2002 Dec; 277(51):49438-45. PubMed ID: 12384504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.